QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Paper on statin dose titration patterns and subsequent cardiovascular events, co-authored by Quantify, has been published
The paper “Statin Dose Titration Patterns and Subsequent Major Cardiovascular Events in very High-Risk Patients – Estimates from Swedish Population-based Registry Data”, co-authored by Quantify’s Jonas Banefelt and Maria Lindh has been published in European Heart Journal – Quality of Care and Clinical Outcomes.
The paper ‘Fragility fractures in Europe: burden, management and opportunities’, co-authored by Quantify, has been published in Archives of Osteoporosis
The paper ‘Fragility fractures in Europe: burden, management and opportunities’, co-authored by Quantify’s Fredrik Borgström, Linda Karlsson, Gustaf Ortsäter and Nicholas Norton, has been published in Archives of Osteoporosis.
Quantify announces new CEO
Quantify is pleased to announce the appointment of Kirk Geale as the new CEO of Quantify Research, replacing Åsa By after 7 highly successful years. Quantify is grateful to Åsa for the visionary leadership and energy she brought to the team, which grew significantly into a large team of highly competent researchers. We wish her great success in her future endeavours! Our new CEO, Kirk, has been with Quantify […]
Quantify Publishes Paper on Cost-Effectiveness of Patiromer in Combination with RAAS Inhibitors for CKD in Sweden in PharmacoEconomics
The paper ‘Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden’, co-authored by Quantify, has been published in PharmacoEconomics. Read the full article here.
